stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Gross margin
10x Genomics's gross margin over the twelve months to 30 September 2026 was 71.9%, up 2.8 percentage points from fiscal 2025 (69.1%). Over the past ten years it has ranged from 66.2% (fiscal 2023) to 85.1% (fiscal 2017); the current reading is higher than 33% of that period. That is above the Medical Devices industry median of 57.8% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 69.1% | 1.19 |
| FY2024 | 67.9% | 1.71 |
| FY2023 | 66.2% | (10.54) |
| FY2022 | 76.7% | (8.20) |
| FY2021 | 84.9% | 4.45 |
| FY2020 | 80.4% | 5.26 |
| FY2019 | 75.2% | (5.23) |
| FY2018 | 80.4% | (4.73) |
| FY2017 | 85.1% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 75.0% | 0.47 |
| Jun 2026 | 74.5% | 4.09 |
| Mar 2026 | 70.4% | 2.30 |
| Dec 2025 | 68.1% | 0.77 |
| 27 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| PODD Insulet Corporation compare | 71.9% |
| SNN Smith & Nephew SNATS, Inc. compare | 70.5% |
| TXG 10x Genomics | 70.0% |
| GMED Globus Medical, Inc. compare | 69.1% |
| PEN Penumbra, Inc. compare | 68.0% |
| HAE Haemonetics Corporation compare | 59.6% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 51.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 51.3% |
| BRKR Bruker Corporation compare | 47.7% |
| Medical Devices industry median | 57.8% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement